| Trial ID: | L0214 |
| Source ID: | NCT00772772
|
| Associated Drug: |
Vitamin D3
|
| Title: |
Vitamin D Repletion in Chronic Kidney Disease
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00772772/results
|
| Conditions: |
Chronic Kidney Disease
|
| Interventions: |
DRUG: Vitamin D3
|
| Outcome Measures: |
Primary: Change in Endotoxin Activity, Endotoxin Activity as measured by the Endotoxin Activity Assay. This measurement was made at baseline and after 8 weeks of therapy with Vitamin D3. The measurement of the assay is unitless. It is not based on an absolute amount of endotoxin, but rather the proportion of the theoretical maximal response of the patient and ranges from 0 (lowest) to 1 (highest)., baseline and 8 weeks | Secondary: Blood Pressure, after 8 weeks of vitamin D therapy|Intestinal Permeability, after 8 weeks of vitamin D therapy|Nuclear Magnetic Resonance (NMR) Lipoprotein Profile, after 8 weeks of vitamin D therapy|25-hydroxy Vitamin D (25-OH Vitamin D), 25-OH Vitamin D levels were measured in patients with chronic kidney disease at baseline and after 8 weeks of treatment with Vitamin D3 30000 units weekly., after 8 weeks of vitamin D therapy|1, 25-OH Vitamin D, after 8 weeks of vitamin D therapy
|
| Sponsor/Collaborators: |
Sponsor: Rockefeller University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
EARLY_PHASE1
|
| Enrollment: |
12
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2008-03
|
| Completion Date: |
2009-10
|
| Results First Posted: |
2011-06-13
|
| Last Update Posted: |
2015-01-15
|
| Locations: |
Rockefeller University, New York, New York, 10065, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00772772
|
